Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

TitleParent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.
Publication TypeJournal Article
Year of Publication2003
AuthorsArnold, EL, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume42
Issue12
Pagination1443-50
Date Published2003 Dec
ISSN0890-8567
KeywordsAdolescent, Adult, Affect, Aggression, Autistic Disorder, Child, Clinical Trials as Topic, Dopamine Antagonists, Double-Blind Method, Endpoint Determination, Female, Humans, Male, Observer Variation, Parent-Child Relations, Placebos, Research Design, Risperidone, Severity of Illness Index, Stereotyped Behavior, Treatment Outcome
Abstract

A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales.

DOI10.1111/j.1751-7893.2009.00137.x
Alternate JournalJ Am Acad Child Adolesc Psychiatry